Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...

The sNDA for empagliflozin (Jardiance) to reduce the risk of cardiovascular death and hospitalization for heart failure and slow kidney function decline in adults with chronic heart failure with ...

Heart failure (HF) imposes a large and growing burden on the population, with a prevalence that is projected to increase to more than 8 million adults by 2030. The high risk of morbidity and mortality ...

Please provide your email address to receive an email when new articles are posted on . “The EMPEROR-Reduced trial required patients to be treated for heart failure, but did not mandate specific doses ...

Bracknell, UK, 5 October 2023 – The National Institute for Health and Care Excellence (NICE) has today announced that empagliflozin (Jardiance ®) is recommended for use as an option for treating ...

"These findings suggest that small variations in the amount of fluid given to a patient with sepsis, or the decision to give less fluid to a patient because they have heart failure, may not have a ...

An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure ...

It is important that all adults with chronic heart failure with reduced ejection fraction are given all appropriate medications at an optimal tolerated dose to best manage their condition and provide ...

In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction. Empagliflozin reduces the risk for heart ...

What instructions should be given to a patient with heart failure with reduced ejection fraction to prevent exacerbation of heart failure? Patients should be counselled on the importance of adherence ...